Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents

doi:10.12092/j.issn.1009-2501.2019.08.017

Abstract

Abstract:

Liver cancer is one kind of the digestive system cancer which is seriously threatening the health of human. The incidence and mortality of liver cancer rank as the fourth and second in China, respectively. Surgical treatment has its own limitations, and conventional chemotherapy drugs have severe side effects with no obvious survival benefits. In recent years, molecular targeted therapy, which can selectively kill tumor cells and has less damage to the body, has been a new research direction in the field of tumor therapy. Small molecule tyrosine kinase inhibitors (TKIs), a family of molecular targeted drugs, have become one of the mainstreams in anti-hepatocarcinoma research. In this paper we briefly summarize the latest clinical trials of small molecule tyrosine kinase inhibitors, including those both on the market and in clinical trials.

Key words: hepatocellular carcinoma, small molecule tyrosine kinase inhibitors, clinical research

CLC Number:

R735.7

CHANG Qingqing, PENG Ying, WANG Guangji, SUN Jianguo. Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 948-956.

References

［1］李芸, 李兵胜, 张卫芳, 等. miR-146a G＞C基因多态性与中国原发性肝癌患者遗传易感性的Meta分析［J］. 中国临床药理学与治疗学, 2017, 22(7): 779-786.
［2］Keating , Gillian M. Sorafenib: a review in hepatocellular carcinoma［J］. Target Oncol, 2017, 12(2): 243-253.
［3］陆伦根. 原发性肝癌的早期筛查及诊断［J］. 临床肝胆病杂志, 2017, 33(7): 1257-1261.
［4］Dawkins J, Webster RM. The hepatocellular carcinoma market ［J］. Nat Rev Drug Discov, 2019, 18(1): 13-14.
［5］李爱军, 马森林, 吴孟超. 分子靶向药物在肝癌治疗中的作用［J］. 肝胆胰外科杂志, 2015, 27(3): 255-258.
［6］Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial ［J］. J Clin Oncol, 2013, 31(32): 4067- 4075.
［7］Johnson PJ, Qin S, Park JW , et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK- FL study［J］. J Clin Oncol, 2013, 31(28): 3517-3524.
［8］Cainap C, Qin S, Huang WT, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial ［J］. J Clin Oncol, 2015, 33(2): 172-179.
［9］Cheng AL, Thongprasert S, Lim HY, et al. Randomized, open-label phase 2 study comparing frontline dovitinib vs sorafenib in patients with advanced hepatocellular carcinoma［J］. Hepatology, 2016, 64(3): 774-784.
［10］Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial ［J］. JAMA, 2014, 312: 57-67.
［11］McNamara MG, Le LW, Horgan AM, et al. A phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma ［J］. Cancer, 2015, 121(10): 1620-1627.
［12］Zhu YJ, Zheng B, Wang HY, et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer ［J］. Acta Pharmacol Sin, 2017, 38(5): 614-622.
［13］Schwartz JD. Sorafenib in advanced hepatocellular carcinoma ［J］. N Engl J Med, 2008, 359(23): 378-390.
［14］Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma［J］. J Clin Oncol Official J Am Soc Clin Oncol, 2008, 26(15_suppl): 4509.
［15］Pressiani T, Boni C, Rimassa L, et al. Sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (HCC): Safety and efficacy in Child-Pugh (CP) class A and B patients ［J］. J Clin Oncol, 2012, 30(4_suppl): 306.
［16］秦叔逵, 龚新雷. 索拉非尼治疗原发性肝癌的研究进展［J］. 临床肿瘤学杂志, 2008, 13(12): 1057-1068.
［17］Guedes LCR, Cristiane M, Daniel B, et al. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study ［J］. Invest New Drugs, 2018, 36(5): 911-918.
［18］Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma［J］. Eur J Cancer, 2011, 47(14): 2117-2127.
［19］Ghassan K, Abou A, Donna N, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802(Alliance) ［J］. J Clin Oncol, 2016, 1: 21-23.
［20］Zhu AX, Rosmorduc O, Evans TRJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma ［J］. J Clin Oncol, 2015, 33(6): 559-566.
［21］Trojan J, Waidmann O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma ［J］. J Hepatocell Carcinoma, 2016, 3: 31-36.
［22］Rimassa L, Pressiani T, Personeni N, et al. Regorafenib for the treatment of unresectable hepatocellular carcinoma［J］. Expert Rev Anticancer Ther, 2017, 17(7): 567-576.
［23］Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity ［J］. Int J Cancer, 2011, 129(1): 245-255.
［24］Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancet, 2017, 389(10064): 56-66.
［25］李槐. 针对"瑞戈非尼用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照Ⅲ期临床试验"导读［J］. 肝癌电子杂志, 2017, 4(1): 3-12.
［26］Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial ［J］. J Hepatol, 2018, 69(2): 353-358.
［27］Baxter MA, Glen H, Evans TR. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma ［J］. Future Oncol, 2018, 14(20): 2021-2029.
［28］Okamoto K, Ikemori-Kawada M, Jestel A, et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization［J］. ACS Med Chem Lett, 2015, 6(1): 89-94.
［29］Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial ［J］. Lancet, 2018, 391(10126): 1163-1173.
［30］Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date ［J］. J Hepatocell Carcinoma, 2019, 6: 31-39.
［31］Kudo M. Lenvatinib in advanced hepatocellular carcinoma［J］. Liver Cancer, 2017, 6(4): 253-263.
［32］Kudo M. Cabozantinib as a second-line agent in advanced hepatocellular carcinoma ［J］. Liver Cancer, 2018, 7: 123-133.
［33］Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study ［J］. Ann Oncol, 2017, 28(3): 528-534.
［34］Abou-Alfa GK, Tim M, Ann-Lii C, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma［J］. N Engl J Med, 2018, 379(1): 54-63.
［35］Qin S. Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, openlabel trial ［C］. Asco Meeting Abstracts, 2014, 32.
［36］Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo［J］. Cancer Sci, 2011, 102(7): 1374-1380.
［37］Kong Y, Sun L, Hou Z, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma ［J］. Oncotarget, 2017, 8(62): 105596-105605.
［38］Yingling JM, Mcmillen WT, Yan L, et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor［J］. Oncotarget, 2018, 9(6): 6659-6677.
［39］Serova M, Annemilai TR, Célia DS, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients ［J］. Oncotarget, 2015, 6(25): 21614-21627.
［40］Ikeda M, Morimoto M, Tajimi M, et al. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma ［J］. Invest New Drugs, 2019, 37(1): 118-126.
［41］Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study ［J］. Lancet Oncol, 2009, 10(8): 794-800.
［42］Llovet JM, Decaens T, Raoul JL, et al. 1398 brivanib versus placebo in patients with advanced hepatocellular carcinoma (hcc) who failed or were intolerant to sorafenib: results from the phase 3 brisk-ps study ［J］. J Clin Oncol, 2013, 31(28): 3509.
［43］De RL, Blanc JF. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma ［J］. Expert Opin Emerg Drugs, 2017, 22(2): 175-190.
［44］Jordi M, Angel JDLR, Fernando D, et al. Targeting tyrosine kinase receptors in hepatocellular carcinoma ［J］. Curr Cancer Drug Targets, 2013, 13(3): 300-312.
［45］刘琦. mRECIS标准在评估原发性肝癌治疗疗效肿瘤活性的临床价值［D］. 南方医科大学, 2014.
［46］Lencioni R, Montal R, Torres F, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC ［J］. J Hepatol, 2017, 66(6): 1166-1172.
［47］Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma ［J］. Semin Liver Dis, 2010, 30(1): 52-60.

[1]	ZHONG Wei, SHI Shuxia, QIN Qinyue, YU Guo. Measurement tools and rationality evaluation of clinical research coordinator's work ability and workload [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 937-947.
[2]	WU Xianchuang, LIU Yuxin, NIU Yuji, HE Jinjin, QIAO Hui, ZHANG Leilei. Mechanism of DCLK1 transcriptional regulation in HCC [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1241-1246.
[3]	YE Kaili, ZHENG Wen, YE Qifa, YANG Lan . Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1086-1094.
[4]	YU Saihong, ZHENG Xiaoliang, PU Yiyi, YAN Dongmei, WANG Xiaoju, YU Jie. Reversal of 5-fluorouracil resistance in hepatocellular carcinoma cells by inhibiting ribonucleotide reductase M2 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 729-737.
[5]	SONG Ruzheng, PENG Ying, WANG Guangji, SUN Jianguo. Commonly used quantitative proteomics research techniques and their application in the study of pathogenesis of liver-derived diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 570-578.
[6]	LI Qingna, HUANG Ke, LU Fang, ZHAO Yang, QIU Panbo, WANG Shuge, GAO Rui. Characteristic and development of standard operating procedure of electronic data management in traditional Chinese medicine clinical research [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 550-554.
[7]	HUANG Kang, LI Ling, YE Qifa, PENG Guizhu. Expression of long non-coding RNA LINC00844 in hepatocellular carcinoma and its inhibiting effect on cell proliferation and migration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 366-372.
[8]	GUO Wei, XIE Linli, CAO Liya, XIE Jiangchuan, XIA Peiyuan, CHEN Yongchuan. Analysis of the current status of clinical drug trial institutions in Chongqing and reflections on the establishment of regional institutions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1125-1130.
[9]	CHE Jinjing. Application of biomarkers in clinical development of biologics and bioanalytical strategies [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 22-31.
[10]	YANG Shucai，ZHANG Li，LIU Liping，DENG Weijie，ZHOU Jie，LIU Hui，ZHANG Baohu，JIN Tao. Effect of hypoxia-inducible factor 2α on chemoresistance of hepatocellular carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 630-636.
[11]	TIAN Jing, MENG Qiuhua, LIANG Qiuyun, DONG Min. Research progress in the associations of metabolic diseases and therapeutic drugs with hepatocellular carcinomas [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 103-110.
[12]	YUAN Gang, HU Airong, HU Yaoren, ZENG Chuanli, ZHU Dedong, SHI Xiaojun. Clinical efficacy and long-term prognosis of entecavir and adefovir dipivoxil in the treatment of compensatory hepatitis B cirrhosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 170-174.
[13]	CAI Min, XU Liu, SHEN Lan, ZHANG Jie. Expression of long-chain non-coding RNA FOXN3-AS2 in hepatocellular carcinoma and its effect on proliferation and invasion of hepatoma cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1246-1251.
[14]	XIAO Liang, ZHENG Gaozhe, HUANG Yumin. Research progress on risk-based management in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 955-960.
[15]	LI Yun, LI Bingsheng, ZHANG Weifang, LI Yixiu, LI Chun, PENG Juan, LAI Xin, ZHU Jing, XU Ruilai, XIONG Aizhen. Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 779-786.